YiChang HEC ChangJiang Pharmaceutical Croissance future
Future contrôle des critères 0/6
YiChang HEC ChangJiang Pharmaceutical devrait augmenter son chiffre d'affaires de 2% par an.
Informations clés
n/a
Taux de croissance des bénéfices
n/a
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 10.8% |
| Taux de croissance des recettes | 2.0% |
| Rendement futur des capitaux propres | 18.6% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 16 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07
Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 5,780 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 5,620 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 5,444 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 5,540 | 1,648 | -398 | 453 | N/A |
| 3/31/2024 | 5,917 | 1,820 | 340 | 1,063 | N/A |
| 12/31/2023 | 6,295 | 1,993 | 1,078 | 1,673 | N/A |
| 9/30/2023 | 5,978 | 1,566 | 1,604 | 2,233 | N/A |
| 6/30/2023 | 5,661 | 1,139 | 2,130 | 2,792 | N/A |
| 3/31/2023 | 4,703 | 608 | 1,488 | 2,246 | N/A |
| 12/31/2022 | 3,745 | 77 | 847 | 1,700 | N/A |
| 9/30/2022 | 2,875 | -18 | 108 | 826 | N/A |
| 6/30/2022 | 2,005 | -113 | -630 | -48 | N/A |
| 3/31/2022 | 1,459 | -351 | -936 | -355 | N/A |
| 12/31/2021 | 914 | -588 | -1,242 | -663 | N/A |
| 9/30/2021 | 690 | -436 | -1,544 | -582 | N/A |
| 6/30/2021 | 467 | -285 | -1,845 | -501 | N/A |
| 3/31/2021 | 1,407 | 277 | -1,232 | 399 | N/A |
| 12/31/2020 | 2,348 | 839 | -619 | 1,299 | N/A |
| 9/30/2020 | 3,792 | 1,204 | -23 | 1,688 | N/A |
| 6/30/2020 | 5,236 | 1,568 | 574 | 2,076 | N/A |
| 3/31/2020 | 5,730 | 1,743 | 348 | 1,935 | N/A |
| 12/31/2019 | 6,224 | 1,919 | 122 | 1,794 | N/A |
| 9/30/2019 | 5,162 | 1,598 | -282 | 1,468 | N/A |
| 6/30/2019 | 4,099 | 1,276 | -686 | 1,141 | N/A |
| 3/31/2019 | 3,305 | 1,109 | -534 | 928 | N/A |
| 12/31/2018 | 2,510 | 943 | -381 | 715 | N/A |
| 9/30/2018 | 2,466 | 961 | -15 | 878 | N/A |
| 6/30/2018 | 2,422 | 980 | 351 | 1,041 | N/A |
| 3/31/2018 | 2,012 | 813 | N/A | 856 | N/A |
| 12/31/2017 | 1,602 | 647 | N/A | 671 | N/A |
| 9/30/2017 | 1,325 | 557 | N/A | 546 | N/A |
| 6/30/2017 | 1,048 | 467 | N/A | 422 | N/A |
| 3/31/2017 | 995 | 424 | N/A | 409 | N/A |
| 12/31/2016 | 942 | 381 | N/A | 397 | N/A |
| 9/30/2016 | 904 | 354 | N/A | 391 | N/A |
| 6/30/2016 | 866 | 327 | N/A | 385 | N/A |
| 3/31/2016 | 779 | 297 | N/A | 336 | N/A |
| 12/31/2015 | 693 | 266 | N/A | 287 | N/A |
| 9/30/2015 | 637 | 236 | N/A | 196 | N/A |
| 6/30/2015 | 581 | 207 | N/A | 104 | N/A |
| 3/31/2015 | 511 | 171 | N/A | 117 | N/A |
| 12/31/2014 | 441 | 135 | N/A | 130 | N/A |
| 12/31/2013 | 316 | 58 | N/A | 52 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de 1558 est supérieure au taux d'épargne ( 2.3% ).
Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de 1558 devraient croître plus rapidement que le marché Hong Kong
Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de 1558 devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 1558 ( 2% par an) devrait croître plus lentement que le marché de Hong Kong ( 7.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 1558 ( 2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 1558 devrait être faible dans 3 ans ( 18.6 %).